News Adhera Therapeutics, Inc.

Equities

ATRX

US00687E4061

Market Closed - OTC Markets Other stock markets 18:00:56 17/05/2024 BST			5-day change	1st Jan Change
0.006 ^USD	-25.93%		+15.38%	-80.00%

01-18	Adhera Therapeutics, Inc. Receives Written Notice from Melior Pharmaceuticals II, LLC of Election to Terminate the License Agreement	CI
01-16	Adhera Therapeutics, Inc. Announces the Resignation of Zahed Subhan as Chief Executive Officer	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Adhera Therapeutics, Inc. Receives Written Notice from Melior Pharmaceuticals II, LLC of Election to Terminate the License Agreement	01-18	CI
Adhera Therapeutics, Inc. Announces the Resignation of Zahed Subhan as Chief Executive Officer	01-16	CI
Adhera Therapeutics, Inc. Announces Board Resignations	01-16	CI
Adhera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-20	CI
BigTime Penny Stocks: OTCQB Venture Market Watchlist (WOEN, ATRX, EDXC, CBDS, OMTK)	17/10/23	AQ
Adhera Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	21/08/23	CI
Thinking about buying stock in Vistagen Therapeutics, Origin Materials, MedAvail Holdings, United States Lime & Minerals, or Adhera Therapeutics?	10/08/23	PR
Adhera Therapeutics, Inc. announced that it has received $0.105 million in funding	21/06/23	CI
Adhera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	22/05/23	CI
Adhera Therapeutics, Inc. announced that it has received $0.1 million in funding	27/04/23	CI
Adhera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	31/03/23	CI
Adhera Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	30/03/23	CI
Adhera Therapeutics, Inc. announced that it has received $0.214285 million in funding	01/03/23	CI
Adhera Therapeutics, Inc. announced that it has received $0.364285 million in funding	15/02/23	CI
Adhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 Diabetes	25/01/23	CI
Adhera Therapeutics, Inc. announced that it has received $0.1 million in funding	14/12/22	CI
Adhera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
Reverse Split: 1 of 20	05/10/22	FA
Adhera Therapeutics Announces CEO, Senior Management Changes, Plans for NASDAQ Uplist	19/09/22	AQ
Adhera Therapeutics, Inc. Elects Zahed Subhan as Chairman of the Board	19/09/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Adhera Therapeutics, Inc.

Equities

ATRX

US00687E4061

Summary

Filters